ArticleScience (New York, N.Y.)2022
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.
Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 196 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
196 citing papers in PubMed, 270 citations in OpenAlex.
- Design of Epitope-Focused Vaccines via Epitope Cleavage.ACS central science · 2026Article
- Targeted FcRn to deliver epitope-optimized RBD confers broad-spectrum mucosal protection against SARS-CoV-2.Molecular therapy. Nucleic acids · 2026Article
- A computational method to design broad-spectrum T cell-inducing vaccines applied to Betacoronaviruses.Cell reports methods · 2026Article
- Review
- Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses.Nature communications · 2026Article
- The Role of Human Viral Entry Receptor Mouse Models in Advancing Antiviral Antibodies and Vaccines.Vaccines · 2026Review
- Nanobody-based combination vaccine using licensed protein nanoparticles protects animals against respiratory and viral infections.Nature biomedical engineering · 2026Article
- Rational design of an optimized ferritin nanoparticle vaccine targeting both SARS-CoV-2 and MERS-CoV.Journal of nanobiotechnology · 2026Article
- Cross-clade vaccination to overcome sarbecovirus or merbecovirus neutralization gaps.Cell reports · 2026Article
- Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.NPJ vaccines · 2026Article
- mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.Scientific reports · 2026Article
- Ready-to-load MHC-I nanoparticles for high-throughput T cell screening studies.Science advances · 2026Article
- A designed overlapping variant immunogen pool elicits broad sarbecovirus neutralization.bioRxiv : the preprint server for biology · 2026Article
- Broadly Protective Antibody-Like Vaccines Against Highly Pathogenic Coronaviruses.Journal of medical virology · 2026Article
- mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures.Cell reports · 2026Article
- Hierarchical Functionalisation of UiO-66(Zr)-NHNanomaterials (Basel, Switzerland) · 2026Article
- An mRNA Vaccine with Tandem Mutated HA-NA Confers Protection Against Multiple Strains of H1N1 Influenza.Vaccines · 2026Article
- Exploring coronavirus cell entry with functional viromics.Journal of virology · 2026Review
- SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design.Reviews in medical virology · 2026Review
136 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
22 authors at 7 institutions in 3 countries.
Funding
Abstract
To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health, we designed mosaic nanoparticles that present randomly arranged sarbecovirus spike receptor-binding domains (RBDs) to elicit antibodies against epitopes that are conserved and relatively occluded rather than variable, immunodominant, and exposed. We compared immune responses elicited by mosaic-8 (SARS-CoV-2 and seven animal sarbecoviruses) and homotypic (only SARS-CoV-2) RBD nanoparticles in mice and macaques and observed stronger responses elicited by mosaic-8 to mismatched (not on nanoparticles) strains, including SARS-CoV and animal sarbecoviruses. Mosaic-8 immunization showed equivalent neutralization of SARS-CoV-2 variants, including Omicrons, and protected from SARS-CoV-2 and SARS-CoV challenges, whereas homotypic SARS-CoV-2 immunization protected only from SARS-CoV-2 challenge. Epitope mapping demonstrated increased targeting of conserved epitopes after mosaic-8 immunization. Together, these results suggest that mosaic-8 RBD nanoparticles could protect against SARS-CoV-2 variants and future sarbecovirus spillovers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.